HIV Prevention Clinical Trials Database

A comprehensive source of information on biomedical HIV prevention clinical trials

View Trials Map

Our database allows users to view planned, ongoing, and completed clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.

Search or Filter

Reset filters

Results

showing 1-20 of 489

Trial Name

CAPRISA 012A / SAMBA trial I

Completed
Prevention Option
Antibody Related Research
Start Date
October 1, 2018
End Date
October 31, 2019
Population
Cisgender Women
Country
South Africa
Product Candidate
VRC07-523LS, PGT121
Sponsors
EDCTP, SAMRC
Trial Name

HVTN 300

Ongoing
Prevention Option
HIV Vaccine
Start Date
May 1, 2021
End Date
January 3, 2024
Population
Cisgender Men
Country
United States of America
Product Candidate
CH505TF
Sponsors
NIAID
Trial Name

HVTN 136/ HPTN 092

Ongoing
Prevention Option
HIV Vaccine
Start Date
November 10, 2020
End Date
August 5, 2022
Population
Cisgender Men, Cisgender Women
Country
United States of America
Product Candidate
PGT121.414.LS, VRC07-523LS
Sponsors
NIAID (DAID-ES: 38634)
Trial Name

HPTN 091

Prevention Option
PrEP
Start Date
March 21, 2021
End Date
November 30, 2024
Population
Cisgender Men
Country
Brazil, United States of America
Product Candidate
TAF/FTC (Descovy), TDF/FTC (Truvada)
Sponsors
Gilead, HPTN
Trial Name

ANRS VRI06

Ongoing
Prevention Option
HIV Vaccine
Start Date
March 29, 2021
End Date
September 30, 2024
Population
Cisgender Men, Cisgender Women
Country
France, Switzerland
Product Candidate
CD40.HIVRI.Env, DNA-HIV-PT123, Poly-ICLC, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
ANRS, Emerging Infectious Diseases
Trial Name

IAVI C101

Ongoing
Prevention Option
HIV Vaccine
Start Date
August 1, 2020
End Date
December 1, 2023
Population
Cisgender Men, Cisgender Women
Country
Netherlands, United States of America
Product Candidate
BG505 SOSIP GT1.1 gp140
Sponsors
GSK, IAVI
Trial Name

IPCAVD 010/ HPX1002

Completed
Prevention Option
HIV Vaccine
Start Date
March 28, 2016
End Date
January 3, 2019
Population
Cisgender Men, Cisgender Women
Product Candidate
gp140, Ad26.Mos.HIV, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
Janssen Vaccines & Prevention B.V.
Trial Name

VRC 609

Ongoing
Prevention Option
Antibody Related Research
Start Date
June 21, 2018
End Date
December 31, 2022
Population
Cisgender Men, Cisgender Women
Country
United States of America
Product Candidate
VRC-HIVMAB091-00-AB, EDP
Sponsors
NIAID
Trial Name

HVTN 303

Planned
Prevention Option
HIV Vaccine
Start Date
End Date
Population
Cisgender Men, Cisgender Women
Sponsors
HVTN
Trial Name

IAVI G003

Ongoing
Prevention Option
HIV Vaccine
Start Date
May 23, 2022
End Date
June 30, 2023
Population
Cisgender Men, Cisgender Women
Country
Rwanda, South Africa
Product Candidate
mRNA-1644 (eOD-GT8 60mer)
Trial Name

Purpose 4/ HPTN 103

Planned
Prevention Option
PrEP
Start Date
End Date
Population
Injecting drug users
Product Candidate
Lenacapavir
Trial Name

PURPOSE 3/ HPTN 102

Planned
Prevention Option
PrEP
Start Date
End Date
Population
Cisgender Women
Product Candidate
Lenacapavir, TDF/FTC (Truvada)
Trial Name

VRC 611

Ongoing
Prevention Option
Antibody Related Research
Start Date
March 22, 2022
End Date
December 15, 2022
Population
Cisgender Men
Country
United States of America
Product Candidate
CAP256V2LS
Sponsors
NIAID
Trial Name

CAPRISA 012B / SAMBA trial II

Ongoing
Prevention Option
Antibody Related Research
Start Date
April 1, 2020
End Date
December 31, 2022
Population
Cisgender Women
Country
South Africa
Product Candidate
CAP256V2LS, PGT121, VRC07-523LS
Sponsors
EDCTP, SAMRC
Trial Name

HVTN 139

Ongoing
Prevention Option
HIV Vaccine
Start Date
November 25, 2021
End Date
November 6, 2025
Population
Cisgender Men, Cisgender Women
Country
South Africa
Product Candidate
AdC6-HIVgp140, AdC7-HIVgp140, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI, GLA-SE, CH505TF, gp120
Sponsors
HVTN, NIAID
Trial Name

VIR-111-2001

Ongoing
Prevention Option
HIV Vaccine
Start Date
December 28, 2020
End Date
January 1, 2025
Population
Cisgender Men, Cisgender Women
Country
United States of America
Sponsors
Gates Foundation
Trial Name

RV 460

Ongoing
Prevention Option
HIV Vaccine
Start Date
March 16, 2021
End Date
February 8, 2023
Population
Cisgender Men, Cisgender Women
Country
Kenya
Product Candidate
Env gp145 C.6980 protein, Rehydragel, Env-C Plasmid DNA, ALF43, dmLT
Sponsors
NIAID, US Army Medical Research Directorate-Africa, US Military HIV Research Program, WRAIR
Trial Name

CAPRISA 012C / SAMBA trial III

Ongoing
Prevention Option
Antibody Related Research
Start Date
September 14, 2022
End Date
September 14, 2022
Population
Cisgender Women
Country
South Africa
Sponsors
EDCTP
Trial Name

HVTN 140/ HPTN 101

Ongoing
Prevention Option
HIV Vaccine
Start Date
November 15, 2021
End Date
November 30, 2022
Population
Cisgender Men
Country
Kenya, South Africa, United States of America, Zimbabwe
Product Candidate
PGDM1400LS, VRC07-523LS, PGT121.414.LS
Sponsors
NIAID (DAIDS-ES: 38723)
Trial Name

HVTN 135

Ongoing
Prevention Option
HIV Vaccine
Start Date
November 10, 2020
End Date
June 1, 2024
Population
Adolescents and Young People
Country
South Africa
Product Candidate
GLA-SE, CH505TF, gp120, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
HVTN, NIAID

showing 1-20 of 489